624 related articles for article (PubMed ID: 17049234)
61. 3D-QSAR analysis of conformationally constrained diacylglycerol (DAG) analogues as potent protein kinase C (PK-C) ligands.
Kim SY; Lee J
Bioorg Med Chem; 2004 May; 12(10):2639-44. PubMed ID: 15110845
[TBL] [Abstract][Full Text] [Related]
62. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
63. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
Huang L; Shi A; He F; Li X
Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
[TBL] [Abstract][Full Text] [Related]
64. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
Tintori C; Magnani M; Schenone S; Botta M
Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
[TBL] [Abstract][Full Text] [Related]
65. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
Du J; Qin J; Liu H; Yao X
J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
[TBL] [Abstract][Full Text] [Related]
66. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase.
Zuo Z; Luo X; Zhu W; Shen J; Shen X; Jiang H; Chen K
Bioorg Med Chem; 2005 Mar; 13(6):2121-31. PubMed ID: 15727865
[TBL] [Abstract][Full Text] [Related]
67. Structure-activity relationships and binding mode in the human acetylcholinesterase active site of pseudo-irreversible inhibitors related to xanthostigmine.
Rizzo S; Cavalli A; Ceccarini L; Bartolini M; Belluti F; Bisi A; Andrisano V; Recanatini M; Rampa A
ChemMedChem; 2009 Apr; 4(4):670-9. PubMed ID: 19222043
[TBL] [Abstract][Full Text] [Related]
68. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors.
Sheng R; Lin X; Li J; Jiang Y; Shang Z; Hu Y
Bioorg Med Chem Lett; 2005 Sep; 15(17):3834-7. PubMed ID: 15993600
[TBL] [Abstract][Full Text] [Related]
69. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
70. Computational studies of COX-2 inhibitors: 3D-QSAR and docking.
Kim HJ; Chae CH; Yi KY; Park KL; Yoo SE
Bioorg Med Chem; 2004 Apr; 12(7):1629-41. PubMed ID: 15028256
[TBL] [Abstract][Full Text] [Related]
71. CoMFA and docking studies of 2-phenylindole derivatives with anticancer activity.
Liao SY; Qian L; Miao TF; Lu HL; Zheng KC
Eur J Med Chem; 2009 Jul; 44(7):2822-7. PubMed ID: 19167135
[TBL] [Abstract][Full Text] [Related]
72. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
[TBL] [Abstract][Full Text] [Related]
73. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
[TBL] [Abstract][Full Text] [Related]
74. 3D-QSAR study of 20 (S)-camptothecin analogs.
Lu AJ; Zhang ZS; Zheng MY; Zou HJ; Luo XM; Jiang HL
Acta Pharmacol Sin; 2007 Feb; 28(2):307-14. PubMed ID: 17241535
[TBL] [Abstract][Full Text] [Related]
75. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
[TBL] [Abstract][Full Text] [Related]
76. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
77. 3D-QSAR and molecular docking studies on benzothiazole derivatives as Candida albicans N-myristoyltransferase inhibitors.
Sheng C; Zhu J; Zhang W; Zhang M; Ji H; Song Y; Xu H; Yao J; Miao Z; Zhou Y; Zhu J; Lü J
Eur J Med Chem; 2007 Apr; 42(4):477-86. PubMed ID: 17349719
[TBL] [Abstract][Full Text] [Related]
78. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
[TBL] [Abstract][Full Text] [Related]
79. 2D-SAR and 3D-QSAR analyses for acetylcholinesterase inhibitors.
Niu B; Zhao M; Su Q; Zhang M; Lv W; Chen Q; Chen F; Chu D; Du D; Zhang Y
Mol Divers; 2017 May; 21(2):413-426. PubMed ID: 28275924
[TBL] [Abstract][Full Text] [Related]
80. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
